Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary

Glasspool, Rosalind M. MBBS, PhD, FRCP*; Martín, Antonio González MD; Millan, David BSc, MB ChB, FRCPath; Lorusso, Domenica MD§; Åvall-Lundqvist, Elisabeth MD, PhD; Hurteau, Jean A. MD; Davis, Alison MBBS, MSc, FRACP#; Hilpert, Felix MD, PhD**; Kim, Jae-Weon MD, PhD††; Alexandre, Jérôme MD, PhD‡‡; Ledermann, Jonathan A. MD, FRCP§§

International Journal of Gynecological Cancer: November 2014 - Volume 24 - Issue 9 - p S26–S29
doi: 10.1097/IGC.0000000000000209
Review Articles

Abstract: Squamous cell carcinoma of the ovary is a rare complication of mature cystic teratoma. The epidemiology, pathology, diagnosis, and management of this rare tumor are reviewed. Clinical characteristics, preoperative imaging, and tumor markers may help to predict malignancy preoperatively. Complete cytoreduction should be the aim of surgery. The prognosis for stage 1A disease is good, but for women with advanced or recurrent disease, it is very poor and has not improved in recent years. At present, there are insufficient data to provide clear guidance on the optimal management strategy for advanced disease, and there is a need to gain an understanding of the biology and to develop novel effective therapies. This will require coordinated international collaboration.

*Beatson West of Scotland Cancer Centre, Glasgow, UK (SGCTG); †Medical Oncology Department, MD Anderson Cancer Centre, Madrid, Spain (GEICO); ‡Southern General Hospital, Glasgow, UK (SGCTG); §Gynecologic Oncology Unit, Fondazione IRCCS National Cancer institute of Milan (MITO), Milan, Italy; ‖Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden (NSGO); ¶Division of Gynecologic Oncology, NorthShore University Health System, University of Chicago Pritzker School of Medicine, Evanston, IL (GOG); #The Canberra Hospital, Canberra, Australia (ANZGOG); **University Hospital of Schleswig-Holstein Campus, Kiel, Germany (AGO); ††Department of Obstectrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea (KGOG); ‡‡Medical Oncology, Cochin-Hôtel Dieu, Paris Descartes University, Paris, France (GINECO); and §§UCL Cancer Institute, London, UK (NCRI/MRC).

Address correspondence and reprint requests to Rosalind M. Glasspool, MBBS, PhD, FRCP, Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN, United Kingdom. E-mail: ros.glasspool@ggc.scot.nhs.uk.

The authors declare no conflicts of interest.

Received April 17, 2014

Received in revised form June 9, 2014

Accepted June 9, 2014

© 2014 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.